A Phase 2 interventional study of EDP-938 and Placebo in Respiratory Syncytial Virus (RSV), sponsored by Enanta Pharmaceuticals, Inc. Completed at 78 sites in 15 countries. Open to participants aged 28 Days to 36 Months. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
This is a randomized, double-blind, dose ranging, placebo-controlled study in respiratory syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to 36 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and antiviral activity of a 5 day treatment with EDP-938.
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EDP-938, oral suspension, once daily for 5 days
Drug: EDP-938
Matching placebo, orally, once daily for 5 days
Drug: Placebo
Oral suspension
Placebo oral suspension to match EDP-938
Part 1: Concentrations of EDP-938 in Plasma
Plasma concentrations of EDP-938 were assessed at the designated time points.
Time frame: 3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5
Part 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.
Time frame: Day 1 to Day 28
Part 2: Model-Adjusted Daily Change From Baseline in Respiratory Syncytial Virus (RSV) Shedding in Nasal Swab Samples
Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV ribonucleic acid (RNA) viral load and was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation is used to estimate the denominator degrees of freedom.
Time frame: Baseline and pre-dose on Days 3, 5, 9, and 14
Pooled Population: Model-Adjusted Daily Change From Baseline in RSV Shedding in Nasal Swab Samples
Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV RNA viral load and was measured using RT-qPCR from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed.The Satterthwaite approximation is used to estimate the denominator degrees of freedom.
Time frame: Baseline and pre-dose on Days 3, 5, 9, and 14
Part 1 and Part 2: Area Under the Curve (AUC) for RSV RNA Viral Load
The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation.
Time frame: Pre-dose on Day 1 through pre-dose on Days 3, 5, 9 and 14
Pooled Population: AUC of Change From Baseline in RSV RNA Viral Load
The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation was used to estimate the denominator degrees of freedom.
Time frame: Baseline (Pre-dose on Day 1) through pre-dose on Days 3, 5, 9 and 14
Part 1: Daily Change From Baseline in RSV Shedding in Nasal Swab Samples
Daily change from baseline in RSV shedding in nasal swab samples was defined as the absolute daily change from baseline in RSV RNA viral load and measured using RT-qPCR from nasal swabs.
Time frame: Baseline to pre-dose on Days 3, 5, 9, and Day 14
Part 1 and Part 2: Percentage of Participants With RSV RNA Viral Load Below the Limit of Detection (LOD)
The RSV RNA viral load was measured using RT-qPCR from nasal swabs.
Time frame: Pre-dose on Days 3, 5, 9 and 14
Pooled Population: Percentage of Participants With RSV RNA Viral Load Below the LOD
The RSV RNA viral load was measured using RT-qPCR from nasal swabs.
Time frame: Pre-dose on Days 3, 5, 9 and 14
Part 1 and Part 2: Time to RSV RNA Viral Load Being Undetectable
Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load target not detected (TND) after which no further samples had detectable RSV RNA viral load - date of first dose.
Time frame: Day 1 to Day 28
Pooled Population: Time to RSV RNA Viral Load Being Undetectable
Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load TND after which no further samples had detectable RSV RNA viral load - date of first dose.
Time frame: Day 1 to Day 28
Part 2: Number of Participants Who Experienced a TEAE
TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.
Time frame: Day 1 to Day 28
Pooled Population: Number of Participants Who Experienced a TEAE
TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.
Time frame: Day 1 to Day 28
Part 2: Concentrations of EDP-938 in Plasma
Plasma concentrations of EDP-938 were assessed at the designated time points.
Time frame: 3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5
Pooled Population: Concentrations of EDP-938 in Plasma
Plasma concentrations of EDP-938 were assessed at the designated time points.
Time frame: 3 hours post-dose on Day 1 and pre-dose on Day 2 (hospitalized participants only), Day 3, and Day 5
Part 2: Time to First Hospital Discharge for Hospitalized Participants
Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.
Time frame: Day 1 to Day 28
Pooled Population: Time to First Hospital Discharge for Hospitalized Participants
Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.
Time frame: Day 1 to Day 28
Part 2: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug
For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.
Time frame: Day 1 to Day 28
Pooled Population: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug
For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.
Time frame: Day 1 to Day 28
Part 2: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation case report form (CRF). The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Pooled Population: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation CRF. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Part 2: Time to Mechanical Ventilation for Hospitalized Participants
Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.
Time frame: Day 1 to Day 28
Pooled Population: Time to Mechanical Ventilation for Hospitalized Participants
Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.
Time frame: Day 1 to Day 28
Part 2: Percentage of Hospitalized Participants Who Required Mechanical Ventilation
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Pooled Population: Percentage of Hospitalized Participants Who Required Mechanical Ventilation
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Part 2: Percentage of Hospitalized Participants Who Died During the Study
The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Pooled Population: Percentage of Hospitalized Participants Who Died During the Study
The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Part 2: Time to Hospitalization for Initial Outpatients Who Were Subsequently Hospitalized
Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.
Time frame: Day 1 to Day 28
Pooled Population: Time to Hospitalization for Initial Outpatients Who Were Subsequently Hospitalized
Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.
Time frame: Day 1 to Day 28
Part 2: Percentage of Outpatients Who Were Subsequently Hospitalized or Died
Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Pooled Population: Percentage of Outpatients Who Were Subsequently Hospitalized or Died
Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
Time frame: Day 1 to Day 28
Part 2: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized
Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver Respiratory Syncytial Virus (RSV) Foundation (ReSVinet) score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.
Time frame: Day 1 to Day 14
Pooled Population: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized
Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver ReSVinet score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.
Time frame: Day 1 to Day 14
A total of 99 participants were enrolled at 78 sites across 15 countries between April 2022 and August 2024.
| Milestone | Part 1, Group 1: EDP-938 | Part 1, Group 2: EDP-938 | Part 1, Group 1: Placebo | Part 1, Group 2: Placebo | Part 2, Group 1: EDP-938 | Part 2, Group 2: EDP-938 | Part 2, Group 1: Placebo | Part 2, Group 2: Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 22 | 14 | 11 | 6 | 20 | 16 | 6 | 4 |
| Treated with 5 mg/kg edp-938 | 14 | 13 | 0 | 0 | 8 | 15 | 0 | 0 |
| Treated with 7.5 mg/kg edp-938 | 9 | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Treated with placebo | 0 | 0 | 11 | 6 | 0 | 0 | 6 | 4 |
| Completed | 22 | 12 | 11 | 4 | 19 | 15 | 6 | 4 |
| Not completed | 0 | 2 | 0 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Plasma concentrations of EDP-938 were assessed at the designated time points.
| ng/mL | Part 1: EDP-938 5mg/kg (≥ 28 Days to < 3 Months) | Part 1: EDP-938 5mg/kg (≥ 3 Months to < 6 Months) | Part 1: EDP-938 5mg/kg (≥ 6 Months to < 12 Months) | Part 1: EDP-938 5mg/kg (≥ 12 Months to ≤ 36 Months) | Part 1: EDP-938 7.5 mg/kg (≥ 12 Months to ≤ 36 Months) |
|---|---|---|---|---|---|
| Day 1 | 1132.222 ± 397.4289 | 1989.500 ± 1331.5646 | 1819.286 ± 809.9508 | 1420.000 ± 604.8140 | 1428.250 ± 817.4801 |
| Day 2 | 368.400 ± 149.8741 | 399.250 ± 423.9515 | 502.350 ± 379.6487 | 249.675 ± 294.5416 | 238.900 ± 239.0287 |
| Day 3 | 448.000 ± 229.1026 | — | 346.000 ± 54.7449 | 97.533 ± 64.9043 | 116.250 ± 43.4871 |
| Day 5 | 528.563 ± 284.6010 | 201.750 ± 98.6623 | 431.429 ± 637.5664 | 252.043 ± 329.2155 | 180.622 ± 158.3268 |
TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.
| Participants | Part 1: EDP-938 | Part 1: Placebo |
|---|---|---|
| Part 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | 14 | 9 |
Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV ribonucleic acid (RNA) viral load and was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation is used to estimate the denominator degrees of freedom.
| log10 copies/mL | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Day 3 | -1.33 ± 0.297 | -0.37 ± 0.533 |
| Day 5 | -3.04 ± 0.354 | -1.62 ± 0.627 |
| Day 9 | -3.65 ± 0.381 | -3.22 ± 0.680 |
| Day 14 | -4.87 ± 0.388 | -5.71 ± 0.677 |
Daily change from baseline in RSV shedding was defined as the daily change from baseline in RSV RNA viral load and was measured using RT-qPCR from nasal swabs. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by Day interaction term as factors. An unstructured covariance matrix was imposed.The Satterthwaite approximation is used to estimate the denominator degrees of freedom.
| log10 copies/mL | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Day 3 | -1.53 ± 0.192 | -1.36 ± 0.331 |
| Day 5 | -2.95 ± 0.230 | -2.62 ± 0.392 |
| Day 9 | -4.57 ± 0.275 | -3.87 ± 0.475 |
| Day 14 | -5.01 ± 0.278 | -5.35 ± 0.462 |
The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation.
| log10 copies/mL*Days | Part 1: EDP-938 | Part 1: Placebo | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|---|---|
| Day 1 through Day 3 | 17.80 ± 4.522 | 17.26 ± 4.691 | 17.15 ± 4.663 | 16.91 ± 3.266 |
| Day 1 through Day 5 | 25.54 ± 8.301 | 24.55 ± 8.457 | 24.76 ± 7.914 | 26.22 ± 7.069 |
| Day 1 through Day 9 | 36.03 ± 16.229 | 35.20 ± 17.156 | 37.00 ± 13.652 | 40.39 ± 13.371 |
| Day 1 through Day 14 | 42.85 ± 24.990 | 44.16 ± 25.056 | 45.49 ± 21.109 | 42.17 ± 19.864 |
The RSV RNA viral load was measured using RT-qPCR from nasal swabs. The AUC was calculated using the trapezoid rule. The AUC was calculated based on all available assessments collected on Days 1, 3, 5, 9 and 14 and the actual date/time of each assessment was used for the calculation. The model included treatment group (EDP-938, placebo) and Day (3, 5, 9, and 14) as fixed effect, associated baseline, and treatment group by day interaction term as factors. An unstructured covariance matrix was imposed. The Satterthwaite approximation was used to estimate the denominator degrees of freedom.
| log10 copies/mL*Days | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Day 1 through Day 3 | -1.53 ± 0.192 | -1.36 ± 0.331 |
| Day 1 through Day 5 | -6.00 ± 0.540 | -5.33 ± 0.930 |
| Day 1 through Day 9 | -21.04 ± 1.319 | -18.32 ± 2.272 |
| Day 1 through Day 14 | -45.00 ± 2.105 | -41.36 ± 3.619 |
Daily change from baseline in RSV shedding in nasal swab samples was defined as the absolute daily change from baseline in RSV RNA viral load and measured using RT-qPCR from nasal swabs.
| log10 copies/mL | Part 1: EDP-938 | Part 1: Placebo |
|---|---|---|
| Day 3 | -1.68 ± 1.239 | -2.17 ± 1.948 |
| Day 5 | -2.91 ± 1.634 | -3.44 ± 1.585 |
| Day 9 | -5.34 ± 2.338 | -4.41 ± 1.897 |
| Day 14 | -5.11 ± 2.378 | -5.15 ± 2.118 |
The RSV RNA viral load was measured using RT-qPCR from nasal swabs.
| percentage of participants | Part 1: EDP-938 | Part 1: Placebo | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|---|---|
| Day 3 | 0 (0.00 to 10.28) | 8.3 (0.21 to 38.48) | 3.6 (0.09 to 18.35) | 0 (0.00 to 33.63) |
| Day 5 | 12.1 (3.40 to 28.20) | 16.7 (2.09 to 48.41) | 22.2 (8.62 to 42.26) | 0 (0.00 to 33.63) |
| Day 9 | 62.5 (43.69 to 78.90) | 36.4 (10.93 to 69.21) | 28.0 (12.07 to 49.39) | 25.0 (3.19 to 65.09) |
| Day 14 | 61.3 (42.19 to 78.15) | 58.3 (27.67 to 84.83) | 63.0 (42.37 to 80.60) | 88.9 (51.75 to 99.72) |
The RSV RNA viral load was measured using RT-qPCR from nasal swabs.
| percentage of participants | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Day 3 | 1.6 (0.04 to 8.66) | 4.8 (0.12 to 23.82) |
| Day 5 | 16.7 (8.29 to 28.52) | 9.5 (1.17 to 30.38) |
| Day 9 | 47.4 (33.98 to 61.03) | 31.6 (12.58 to 56.55) |
| Day 14 | 62.1 (48.37 to 74.49) | 71.4 (47.82 to 88.72) |
Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load target not detected (TND) after which no further samples had detectable RSV RNA viral load - date of first dose.
| days | Part 1: EDP-938 | Part 1: Placebo | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|---|---|
| Part 1 and Part 2: Time to RSV RNA Viral Load Being Undetectable | 10.59 ± 3.661 | 12.33 ± 3.018 | 12.46 ± 3.235 | 12.19 ± 3.040 |
Time to RSV RNA viral load being undetectable was calculated as: first date of RSV RNA viral load TND after which no further samples had detectable RSV RNA viral load - date of first dose.
| days | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Time to RSV RNA Viral Load Being Undetectable | 11.45 ± 3.570 | 12.27 ± 2.958 |
TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.
| Participants | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Number of Participants Who Experienced a TEAE | 14 | 4 |
TEAEs were defined as any event, side effect, or untoward medical occurrence in a participant enrolled in a clinical study whether or not it was considered to have a causal relationship to the study drug and first occurred or worsened during the post-baseline phase compared to baseline. Clinically significant changes from baseline in vital signs and clinical laboratory results were reported as TEAEs.
| Participants | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Number of Participants Who Experienced a TEAE | 28 | 13 |
Plasma concentrations of EDP-938 were assessed at the designated time points.
| ng/mL | Part 2: EDP-938 5mg/kg (≥ 28 Days to < 3 Months) | Part 2: EDP-938 5mg/kg (≥ 3 Months to < 6 Months) | Part 2: EDP-938 5mg/kg (≥ 6 Months to < 12 Months) | Part 2: EDP-938 7.5 mg/kg (≥ 12 Months to ≤ 36 Months) |
|---|---|---|---|---|
| Day 1 | 1116.286 ± 217.9983 | 1169.903 ± 802.0744 | 1551.429 ± 363.8419 | 1368.111 ± 469.7815 |
| Day 2 | 585.400 ± 119.6089 | 273.500 ± 150.4616 | 140.783 ± 73.3099 | 200.700 ± 134.3896 |
| Day 3 | 194.000 ± NA | 926.000 ± 57.9828 | 112.000 ± NA | 115.967 ± 84.9347 |
| Day 5 | 516.333 ± 247.6697 | 519.714 ± 436.8130 | 69.110 ± 40.4604 | 153.450 ± 102.4372 |
Plasma concentrations of EDP-938 were assessed at the designated time points.
| ng/mL | Combined EDP-938 5mg/kg (≥ 28 Days to < 3 Months) | Combined EDP-938 5mg/kg (≥ 3 Months to < 6 Months) | Combined EDP-938 5mg/kg (≥ 6 Months to < 12 Months) | Combined EDP-938 5mg/kg (≥ 12 Months to ≤ 36 Months) | Combined EDP-938 7.5 mg/kg (≥ 12 Months to ≤ 36 Months) |
|---|---|---|---|---|---|
| Day 1 | 1125.250 ± 321.4278 | 1443.102 ± 1027.5197 | 1685.357 ± 619.0267 | 1420.000 ± 604.8140 | 1396.412 ± 635.3537 |
| Day 2 | 458.817 ± 173.0322 | 323.800 ± 276.9576 | 285.410 ± 293.0727 | 249.675 ± 294.5416 | 221.269 ± 191.0117 |
| Day 3 | 363.333 ± 218.5162 | 926.000 ± 57.9828 | 287.500 ± 125.2478 | 97.533 ± 64.9043 | 116.080 ± 63.8730 |
| Day 5 | 522.918 ± 257.0945 | 404.091 ± 378.3365 | 250.269 ± 472.9799 | 252.043 ± 329.2155 | 167.835 ± 131.6054 |
Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.
| days | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Time to First Hospital Discharge for Hospitalized Participants | 3.93 ± 1.870 | 4.00 ± 3.367 |
Time to first discharge for participants who were hospitalized at randomization was calculated as: date/time of first discharge - date/time of first dose with conversion to days. For participants with continuous hospitalization, the last date of discharge from the continuous hospitalization was used.
| days | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Time to First Hospital Discharge for Hospitalized Participants | 3.71 ± 2.006 | 3.57 ± 2.959 |
For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.
No measurements were reported for this outcome.
For participants were were hospitalized at randomization, time to use of oxygen for hospitalization participants who were not receiving oxygen at the time they received the first dose of study drug was calculated as: first date/time of receiving oxygen - date/time of first dose of study drug with conversion to days.
| days | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Time to Use of Oxygen for Hospitalized Participants Who Were Not Receiving Oxygen at the Time They Received the First Dose of Study Drug | 0.51 ± NA | — |
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation case report form (CRF). The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug | 24.1 (10.30 to 43.54) | 28.6 (3.67 to 70.96) |
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for oxygen supplementation or new increase in oxygen requirements after the first dose of study drug, based on the response of "yes" to the "Is this an increase of oxygen supplementation compared to previous use?" question on the Oxygen Supplementation CRF. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Percentage of Hospitalized Participants Who Required Oxygen Supplementation or Had an Increased Oxygen Requirement After the First Dose of Study Drug | 25.0 (14.39 to 38.37) | 19.0 (5.45 to 41.91) |
Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.
No measurements were reported for this outcome.
Time to mechanical ventilation for participants who were hospitalized at randomization was calculated as: first date/time of mechanical ventilation - date/time of first dose of study drug with conversion to days. Participants who were on mechanical ventilation before their first dose of study drug were excluded from the analysis.
No measurements were reported for this outcome.
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Hospitalized Participants Who Required Mechanical Ventilation | 0 (0.00 to 11.94) | 0 (0.00 to 40.96) |
The numerator in the percentage calculation was defined by the number of participants who developed a new requirement for mechanical ventilation after the first dose of study drug. Participants on mechanical ventilation prior to the first dose of study drug were excluded from analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Percentage of Hospitalized Participants Who Required Mechanical Ventilation | 0 (0.00 to 6.38) | 0 (0.00 to 16.11) |
The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Hospitalized Participants Who Died During the Study | 0 (0.00 to 11.94) | 0 (0.00 to 40.96) |
The percentage of hospitalized participants who died during the study included deaths from any cause. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Percentage of Hospitalized Participants Who Died During the Study | 0 (0.00 to 6.38) | 0 (0.00 to 16.11) |
Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.
No measurements were reported for this outcome.
Time to hospitalization for initial outpatients who are not hospitalized at randomization but subsequently hospitalized was calculated as: first date/time of hospitalization - date/time of first dose with conversion to days.
No measurements were reported for this outcome.
Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Outpatients Who Were Subsequently Hospitalized or Died | 0 (0.00 to 52.18) | 0 (0.00 to 70.76) |
Participants who were hospitalized at randomization were excluded from the analysis. The 95% confidence interval was reported using the Clopper Pearson confidence interval methods.
| percentage of participants | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Percentage of Outpatients Who Were Subsequently Hospitalized or Died | 0 (0.00 to 24.71) | 0 (0.00 to 45.93) |
Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver Respiratory Syncytial Virus (RSV) Foundation (ReSVinet) score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.
| days | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|
| Part 2: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized | 2.60 ± 1.686 | 1.49 ± 0.702 |
Resolution of symptoms was defined as the first of 2 consecutive timepoints where each of the seven symptoms assessed by the Parent/Caregiver ReSVinet score was 0 (not present) or 1 (mild). Time to resolution of symptoms for outpatients who were not hospitalized was calculated as: first date/time of resolution of symptoms - date/time of first dose with conversion to days. Participants who did not achieve resolution and had not been followed through the Day 14 visit or completed the Day 14 questionnaire were censored at Day 14. During the study, the parent(s)/caregiver(s) assessed the severity of RSV-related signs and symptoms. The ReSVinet assessed 7 symptoms, with each symptom being rated from 0 (not present) to 3 (severe), apart from fever which was scored from 0-2. The full range was 0 to 20 with higher scores representing more severe disease.
| days | Combined EDP-938 | Combined Placebo |
|---|---|---|
| Pooled Population: Time to Resolution of Symptoms for Outpatients Who Were Not Hospitalized | 2.42 ± 1.163 | 4.20 ± 5.552 |
Collected over Up to Day 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: EDP-938 | 0/36 (0%) | 0/36 (0%) | 7/36 (19.4%) |
| Part 1: Placebo | 0/16 (0%) | 2/16 (12.5%) | 7/16 (43.8%) |
| Part 2: EDP-938 | 0/34 (0%) | 1/34 (2.9%) | 9/34 (26.5%) |
| Part 2: Placebo | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | Part 1: EDP-938 | Part 1: Placebo | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/36 | 1/16 | 0/34 | 0/10 |
| BronchiolitisInfections and infestations | 0/36 | 1/16 | 0/34 | 0/10 |
| PneumoniaInfections and infestations | 0/36 | 0/16 | 1/34 | 0/10 |
| Event | Part 1: EDP-938 | Part 1: Placebo | Part 2: EDP-938 | Part 2: Placebo |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/36 | 1/16 | 3/34 | 0/10 |
| Myocardial necrosis marker increasedInvestigations | 0/36 | 0/16 | 0/34 | 1/10 |
| AnaemiaBlood and lymphatic system disorders | 0/36 | 0/16 | 0/34 | 1/10 |
| PyrexiaGeneral disorders | 1/36 | 0/16 | 0/34 | 1/10 |
| RashSkin and subcutaneous tissue disorders | 1/36 | 0/16 | 2/34 | 1/10 |
| NasopharyngitisInfections and infestations | 0/36 | 1/16 | 1/34 | 1/10 |
| VomitingGastrointestinal disorders | 0/36 | 1/16 | 0/34 | 0/10 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/36 | 1/16 | 1/34 | 0/10 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 1/36 | 1/16 | 0/34 | 0/10 |
| EczemaSkin and subcutaneous tissue disorders | 1/36 | 1/16 | 1/34 | 0/10 |
Safety Population: Included all participants who received any dose (including partial doses) of any study drug. Participants have been reported according to the actual treatment received. One participant was randomized to 7.5 mg/kg EDP-938, but received 5 mg/kg in error and one participant was randomized to placebo, but received 7.5 mg/kg EDP-938 in error.
| Age, Customized(Participants) | Part 1, Group 1: EDP-938 | Part 1, Group 2: EDP-938 | Part 1, Group 1: Placebo | Part 1, Group 2: Placebo | Part 2, Group 1: EDP-938 | Part 2, Group 2: EDP-938 | Part 2, Group 1: Placebo | Part 2, Group 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| ≥ 28 days to < 3 months | 0 | 9 | 0 | 4 | 0 | 7 | 0 | 2 | 22 |
| ≥ 3 months to < 6 months | 0 | 4 | 0 | 2 | 0 | 8 | 0 | 2 | 16 |
| ≥ 6 months to < 12 months | 7 | 0 | 4 | 0 | 8 | 0 | 3 | 0 | 22 |
| ≥ 12 months to ≤ 36 months | 16 | 0 | 6 | 0 | 11 | 0 | 3 | 0 | 36 |
| Sex: Female, Male(Participants) | Part 1, Group 1: EDP-938 | Part 1, Group 2: EDP-938 | Part 1, Group 1: Placebo | Part 1, Group 2: Placebo | Part 2, Group 1: EDP-938 | Part 2, Group 2: EDP-938 | Part 2, Group 1: Placebo | Part 2, Group 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 5 | 3 | 5 | 11 | 7 | 5 | 1 | 49 |
| Male | 11 | 8 | 7 | 1 | 8 | 8 | 1 | 3 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Part 1, Group 1: EDP-938 | Part 1, Group 2: EDP-938 | Part 1, Group 1: Placebo | Part 1, Group 2: Placebo | Part 2, Group 1: EDP-938 | Part 2, Group 2: EDP-938 | Part 2, Group 1: Placebo | Part 2, Group 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 3 | 3 | 2 | 6 | 6 | 3 | 3 | 38 |
| Not Hispanic or Latino | 11 | 10 | 7 | 4 | 12 | 9 | 3 | 1 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part 1, Group 1: EDP-938 | Part 1, Group 2: EDP-938 | Part 1, Group 1: Placebo | Part 1, Group 2: Placebo | Part 2, Group 1: EDP-938 | Part 2, Group 2: EDP-938 | Part 2, Group 1: Placebo | Part 2, Group 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 2 | 2 | 0 | 0 | 1 | 3 | 0 | 1 | 9 |
| Black or African American | 3 | 0 | 5 | 2 | 3 | 2 | 0 | 0 | 15 |
| White | 18 | 11 | 3 | 2 | 12 | 10 | 4 | 2 | 62 |
| Other | 0 | 0 | 1 | 1 | 2 | 0 | 2 | 0 | 6 |
| Not Reported | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Hospitalization Status on Day 1(Participants) | Part 1, Group 1: EDP-938 | Part 1, Group 2: EDP-938 | Part 1, Group 1: Placebo | Part 1, Group 2: Placebo | Part 2, Group 1: EDP-938 | Part 2, Group 2: EDP-938 | Part 2, Group 1: Placebo | Part 2, Group 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Yes | 16 | 12 | 8 | 5 | 17 | 12 | 4 | 3 | 77 |
| No | 7 | 1 | 2 | 1 | 2 | 3 | 2 | 1 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Aug 2024, 27 months.
Results were first posted in Jul 2025, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-938